Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation

Jinhua Huang; Di Yin; Xia Qin; Mei Yu; Beilei Jiang; Jing Chen; Qing Cao; Zhiguo Tang

doi:10.3389/fped.2022.935118

Frontiers in Pediatrics (Aug 2022)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation

Jinhua Huang,
Di Yin,
Xia Qin,
Mei Yu,
Beilei Jiang,
Jing Chen,
Qing Cao,
Zhiguo Tang

Affiliations

Jinhua Huang: Hefei First People’s Hospital, Hefei, China
Di Yin: Hefei First People’s Hospital, Hefei, China
Xia Qin: Department of Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Mei Yu: Hefei First People’s Hospital, Hefei, China
Beilei Jiang: Hefei First People’s Hospital, Hefei, China
Jing Chen: Department of Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Qing Cao: Department of Infectious Disease, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Zhiguo Tang: Hefei First People’s Hospital, Hefei, China

DOI: https://doi.org/10.3389/fped.2022.935118
Journal volume & issue: Vol. 10

Abstract

Read online

We present a case report of successful treatment with nirmatrelvir/ritonavir (Paxlvoid) for a severe aplastic anemia child with COVID-19, cytopenia, and mixed chimerism of donor hematopoietic cells at 3 months after allogeneic hematopoietic stem cell transplantation. After the 5-day entire course of treatment, the clinical symptoms were relieved, cycle threshold values of ORF1a/b and N genes increased from 22.60 and 22.15 to 34.52 and 33.84, respectively, and the peripheral blood counts gradually recovered without graft failure. Nirmatrelvir/ritonavir can effectively inhibit the replication of SARS-CoV-2 without any significant adverse effects.

Published in Frontiers in Pediatrics

ISSN: 2296-2360 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Pediatrics
Website: http://journal.frontiersin.org/journal/pediatrics

About the journal

Abstract

Keywords